Idiopathic Intracranial Hypertension Progression and Management

Initial Presentation and Classification

IIH can present in three main patterns: Fulminant IIH, Typical IIH, and Atypical IIH, with Typical IIH being the most common form, affecting women of reproductive age with BMI ≥30 kg/m², according to the Journal of Neurology, Neurosurgery and Psychiatry 1
The American Academy of Neurology recommends considering IIH in patients with symptoms such as headache, transient visual obscurations, pulsatile tinnitus, visual blurring, and horizontal diplopia, which are common presenting symptoms, with headache occurring in 92% of patients 3

The International Headache Society notes that headaches may persist despite normalization of intracranial pressure, with 68% of patients continuing to have headaches 6 months after CSF diversion procedures, and 79% having persistent headaches 2 years after CSF diversion 5
Many patients develop migrainous headaches superimposed on ICP-related headaches, as reported in the Journal of Neurology, Neurosurgery and Psychiatry 5

The American Academy of Ophthalmology recommends follow-up intervals based on papilledema grade and visual field status, with severe papilledema requiring monitoring every 1-3 months, according to the Journal of Neurology, Neurosurgery and Psychiatry 5
More frequent monitoring is needed if visual function is worsening, with immediate assessment required for worsening with severe papilledema, as stated in the Journal of Neurology, Neurosurgery and Psychiatry 5

Weight loss, particularly 5-15% of body weight, may lead to disease remission, as noted in the Journal of Neurology, Neurosurgery and Psychiatry 1
Severe papilledema at presentation is a negative prognostic factor, according to the Journal of Neurology, Neurosurgery and Psychiatry 5

IIH may recur throughout life, particularly with weight regain after initial loss, as reported in the Journal of Neurology, Neurosurgery and Psychiatry 1
Pregnancy or hormonal changes may also contribute to recurrence, as stated in Praxis Medical Insights: Practical Summaries of Clinical Guidelines 2

Medical therapy, including acetazolamide and topiramate, shows variable response rates, with treatment failure in 34% at 1 year and 45% at 3 years, according to Praxis Medical Insights: Practical Summaries of Clinical Guidelines 2
Weight management is the only disease-modifying therapy for typical IIH, with sustained weight loss being challenging but essential, as noted in the Journal of Neurology, Neurosurgery and Psychiatry 1